In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about the disappointment surrounding the uptake of Humira biosimilars.
In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium talks about the disappointment surrounding the uptake of Humira biosimilars.
Lockhart spoke about biosimilars at an Asembia 2024 session yesterday but was interviewed earlier this month by Managed Healthcare Executive.
"I think the fact that we haven't seen much uptake of the adalimumab biosimilars yet is disappointing," she said in the interview. "Although at the same time, it seems to be following a pattern that we've seen with a lot of biosimilars especially early on in their availability."
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More